Literature DB >> 24839008

Knockdown of RLIP76 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to daunorubicin in U937 leukemia cells.

Kun Yao1, Hongchang Xing, Wei Yang, Aijun Liao, Bin Wu, Yingchun Li, Rong Zhang, Zhuogang Liu.   

Abstract

RLIP76 is known to play a role in cell growth, division, apoptosis, and chemosensitivity in various malignant cancer cells. However, few studies have been done on the role of RLIP76 in leukemia. In this study, human leukemia cell line U937 was transiently transfected with a RLIP76-targeted short hairpin RNA (shRNA) to investigate the effects of RLIP76 on cellular functions. Real-time PCR and western blot analysis revealed that the expression levels of RLIP76 mRNA and protein in U937 cells were significantly suppressed after transfection with shRNA-containing vector. Knockdown of RLIP76 significantly inhibited cell growth and decreased the colony formation rate, as assessed by trypan blue exclusion and colony formation assay. Flow cytometry analysis showed that reduced RLIP76 expression resulted in cell cycle arrest at G1 phase and induced apoptosis. Meanwhile, western blot analysis demonstrated that RLIP76 knockdown increased expression of Bax, cleaved caspase-3/-9, and cleaved poly (ADP-ribose) polymerase (PARP) but reduced the expression of cyclin D1, cyclin E, and Bcl-2 in U937 cells. Finally, knockdown of RLIP76 in U937 cells also enhanced their chemosensitivity to daunorubicin. Taken together, this study suggests that RLIP76 is a potential target for developing novel therapeutic strategies for leukemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24839008     DOI: 10.1007/s13277-014-2073-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

Review 1.  Epigenetics in acute myeloid leukemia.

Authors:  Christoph Plass; Christopher Oakes; William Blum; Guido Marcucci
Journal:  Semin Oncol       Date:  2008-08       Impact factor: 4.929

2.  Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer.

Authors:  Sharad S Singhal; Jyotsana Singhal; Maya P Nair; A G Lacko; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Int J Oncol       Date:  2007-03       Impact factor: 5.650

3.  HSF-1 interacts with Ral-binding protein 1 in a stress-responsive, multiprotein complex with HSP90 in vivo.

Authors:  Yanzhong Hu; Nahid F Mivechi
Journal:  J Biol Chem       Date:  2003-03-05       Impact factor: 5.157

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  POB1 over-expression inhibits RLIP76-mediated transport of glutathione-conjugates, drugs and promotes apoptosis.

Authors:  Sushma Yadav; Ewa Zajac; Sharad S Singhal; Jyotsana Singhal; Kenneth Drake; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Biochem Biophys Res Commun       Date:  2005-03-25       Impact factor: 3.575

Review 6.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

7.  Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.

Authors:  Purva Bali; Prince George; Pamela Cohen; Jianguo Tao; Fei Guo; Celia Sigua; Anasuya Vishvanath; Anna Scuto; Srinivas Annavarapu; Warren Fiskus; Lynn Moscinski; Peter Atadja; Kapil Bhalla
Journal:  Clin Cancer Res       Date:  2004-08-01       Impact factor: 12.531

8.  Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.

Authors:  Sharad S Singhal; Archana Sehrawat; Mukesh Sahu; Preeti Singhal; Rit Vatsyayan; Poorna Chandra Rao Lelsani; Sushma Yadav; Sanjay Awasthi
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

9.  Role of RLIP76 in lung cancer doxorubicin resistance: I. The ATPase activity of RLIP76 correlates with doxorubicin and 4-hydroxynonenal resistance in lung cancer cells.

Authors:  Sharad S Singhal; Jyotsana Singhal; Rajendra Sharma; Shivendra V Singh; Piotr Zimniak; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Int J Oncol       Date:  2003-02       Impact factor: 5.650

10.  RLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancer.

Authors:  Kathryn Leake; Jyotsana Singhal; Lokesh Dalasanur Nagaprashantha; Sanjay Awasthi; Sharad S Singhal
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

View more
  2 in total

Review 1.  RLIP76 Targeted Therapy for Kidney Cancer.

Authors:  Sharad S Singhal; Jyotsana Singhal; James Figarola; David Horne; Sanjay Awasthi
Journal:  Pharm Res       Date:  2015-05-29       Impact factor: 4.200

Review 2.  RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.

Authors:  Sharad S Singhal; Lokesh Nagaprashantha; Preeti Singhal; Sulabh Singhal; Jyotsana Singhal; Sanjay Awasthi; David Horne
Journal:  Pharm Res       Date:  2017-04-06       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.